EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has signed a Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd, a Singapore-based biotech company. The LOI includes a 120-day exclusivity period during which Chemokine cannot engage in discussions with other potential buyers.
Chemokine, founded by Professor Kah Meng Lim, specializes in molecular supplements and gene modulating formulations. The company has previously granted EUDA exclusive worldwide distribution rights to its next-generation immune health supplement, which EUDA will market as Euda Helix茅. The supplement combines molecular deer placenta, marine collagen, and bioactive antioxidants, utilizing a gene activation model designed to modulate gene expression.
EUDA Health Holdings (NASDAQ: EUDA), fornitore di servizi sanitari con sede a Singapore, ha firmato una Lettera di Intenti (LOI) per l'eventuale acquisizione di Chemokine Pte Ltd, societ脿 biotech anch'essa con sede a Singapore. La LOI prevede un periodo di esclusiva di 120 giorni, durante il quale Chemokine non pu貌 avviare trattative con altri potenziali acquirenti.
Fondata dal professor Kah Meng Lim, Chemokine 猫 specializzata in integratori molecolari e formulazioni per la modulazione genica. In precedenza l'azienda ha concesso a EUDA i diritti esclusivi di distribuzione mondiale del suo integratore immunitario di nuova generazione, che EUDA commercializzer脿 con il nome Euda Helix茅. Il prodotto combina placenta di cervo molecolare, collagene marino e antiossidanti bioattivi, basandosi su un modello di attivazione genica studiato per modulare l'espressione genica.
EUDA Health Holdings (NASDAQ: EUDA), proveedor de servicios de salud con sede en Singapur, ha firmado una Carta de Intenci贸n (LOI) para la posible adquisici贸n de Chemokine Pte Ltd, una empresa biotecnol贸gica tambi茅n radicada en Singapur. La LOI incluye un periodo de exclusividad de 120 d铆as, durante el cual Chemokine no podr谩 mantener conversaciones con otros compradores potenciales.
Chemokine, fundada por el profesor Kah Meng Lim, se especializa en suplementos moleculares y formulaciones para la modulaci贸n g茅nica. La compa帽铆a ya otorg贸 a EUDA los derechos exclusivos de distribuci贸n mundial de su suplemento inmunol贸gico de pr贸xima generaci贸n, que EUDA comercializar谩 como Euda Helix茅. El suplemento combina placenta molecular de ciervo, col谩geno marino y antioxidantes bioactivos, empleando un modelo de activaci贸n g茅nica dise帽ado para modular la expresi贸n de genes.
EUDA Health Holdings (NASDAQ: EUDA)電� 鞁标皜韽ゴ鞐� 氤胳偓毳� 霊� 項姢旒�鞏� 鞝滉车鞐呾泊搿�, 鞁标皜韽ゴ 旮半皹鞚� 氚旍澊鞓ろ厤 旮办梾 Chemokine Pte Ltd毳� 鞛犾灛鞝侅溂搿� 鞚胳垬頃橁赴 鞙勴暅 鞚橅枼靹�(LOI)毳� 觳搓舶頄堨姷雼堧嫟. 鞚� LOI鞐愲姅 Chemokine鞚� 雼るジ 鞛犾灛鞝� 鞚胳垬鞛愳檧 雲检潣毳� 歆勴枆頃� 靾� 鞐嗠弰搿� 頃橂姅 120鞚缄皠鞚� 霃呾爯 旮瓣皠鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
甑愳垬 Kah Meng Lim鞚� 靹る頃� Chemokine鞚� 攵勳瀽 氤挫订鞝滌檧 鞙犾爠鞛� 臁办爤 鞝滍槙鞚� 鞝勲鞙茧 頃╇媹雼�. 鞚� 須岇偓電� 鞚措 彀劯雽� 氅挫棴 瓯搓皶 氤挫订鞝滌潣 鞝� 靹戈硠 霃呾爯 鞙犿喌甓岇潉 EUDA鞐� 攵�鞐枅鞙茧┌, EUDA電� 鞚措ゼ Euda Helix茅霛茧姅 鞚措鞙茧 韺愲Г頃� 鞓堨爼鞛呺媹雼�. 頃措嫻 氤挫订鞝滊姅 攵勳瀽頇旊悳 靷姶 韮滊皹, 頃挫枒 旖滊澕瓴� 氚� 靸濍Μ頇滌劚 頃偘頇旍牅毳� 臁绊暕頃橃棳 鞙犾爠鞛� 氚滍槃鞚� 臁办爤頃橂弰搿� 靹り硠霅� 鞙犾爠鞛� 頇滌劚頇� 氇嵏鞚� 頇滌毄頃╇媹雼�.
EUDA Health Holdings (NASDAQ: EUDA), prestataire de soins bas茅 脿 Singapour, a sign茅 une lettre d'intention (LOI) visant 脿 l'acquisition potentielle de Chemokine Pte Ltd, une soci茅t茅 biotechnologique 茅galement bas茅e 脿 Singapour. La LOI pr茅voit une p茅riode d'exclusivit茅 de 120 jours, pendant laquelle Chemokine ne peut pas engager de n茅gociations avec d'autres acheteurs potentiels.
Fond茅e par le professeur Kah Meng Lim, Chemokine est sp茅cialis茅e dans les suppl茅ments mol茅culaires et les formulations de modulation g茅n茅tique. L'entreprise a ant茅rieurement accord茅 脿 EUDA les droits exclusifs de distribution mondiale de son suppl茅ment immunitaire de nouvelle g茅n茅ration, que EUDA commercialisera sous le nom de Euda Helix茅. Le suppl茅ment combine placenta de cerf mol茅culaire, collag猫ne marin et antioxydants bioactifs, en s'appuyant sur un mod猫le d'activation g茅nique con莽u pour moduler l'expression des g猫nes.
EUDA Health Holdings (NASDAQ: EUDA), ein in Singapur ans盲ssiger Gesundheitsdienstleister, hat eine Absichtserkl盲rung (LOI) zur m枚glichen 脺bernahme von Chemokine Pte Ltd, einem ebenfalls in Singapur ans盲ssigen Biotech-Unternehmen, unterzeichnet. Die LOI beinhaltet eine 120-t盲gige Exklusivit盲tsphase, w盲hrend der Chemokine keine Gespr盲che mit anderen potenziellen K盲ufern f眉hren darf.
Chemokine, gegr眉ndet von Professor Kah Meng Lim, spezialisiert sich auf molekulare Nahrungserg盲nzungsmittel und genmodulierende Formulierungen. Das Unternehmen hat EUDA zuvor die weltweiten Exklusivrechte zur Distribution seines Immungesundheits-Supplements der n盲chsten Generation einger盲umt, das EUDA unter dem Namen Euda Helix茅 vermarkten wird. Das Supplement vereint molekulare Hirschplazenta, marines Kollagen und bioaktive Antioxidantien und nutzt ein Genaktivierungsmodell, das auf die Modulation der Genexpression abzielt.
- Potential acquisition of Chemokine would expand EUDA's biotech capabilities
- Existing exclusive worldwide distribution rights for Euda Helix茅 product
- 120-day exclusivity period secured for acquisition discussions
- Integration with established molecular medicine expertise through Prof. Lim
- No disclosed financial terms or valuation for the potential acquisition
- Acquisition is still in early stages with only LOI signed
- Due diligence process and final agreement yet to be completed
Insights
EUDA's LOI to acquire Chemokine represents early-stage M&A interest with potential synergies but remains highly preliminary.
EUDA Health's signed Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd marks an early exploratory step in what could become a strategic acquisition. The 120-day exclusivity period provides EUDA sufficient time to conduct thorough due diligence while preventing Chemokine from entertaining competing offers.
The companies already have an established relationship, with EUDA holding exclusive worldwide distribution rights to Chemokine's next-generation immune health supplement, which EUDA markets as Euda Helix茅. This existing partnership potentially reduces integration risk and suggests potential synergies are already identified.
Chemokine's scientific foundation appears substantial, led by Prof. Kah Meng Lim, who holds a Ph.D. in Molecular Medicine from the National University of Singapore and has research experience with A*STAR, Singapore's respected national R&D agency. This scientific credibility could enhance EUDA's product portfolio and intellectual property assets.
The Euda Helix茅 product itself combines molecular deer placenta, marine collagen, and various bioactive compounds, utilizing a gene activation model aimed at modulating gene expression. While these claims are scientifically complex, they align with premium positioning in the growing nutraceutical market.
However, investors should note this is merely an LOI, representing the most preliminary stage of M&A activity. No financial terms were disclosed, and the completion of this acquisition remains contingent on due diligence outcomes and subsequent definitive agreements. The news indicates strategic intent but offers minimal concrete details about valuation or integration plans.
SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (鈥淓UDA鈥� or the 鈥淐ompany鈥�), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the 鈥淟OI鈥�) to potentially acquire Chemokine Pte Ltd (鈥淐hemokine鈥�).
EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) days during which it shall not engage in any discussions with any other entity relating to any transaction similar to this potential acquisition.
Chemokine is a Singapore based biotech company focused on molecular supplements and gene modulating formulations including, but not limited to, a next-generation immune health supplement it earlier granted EUDA exclusive worldwide distribution rights to, which EUDA and its subsidiaries will market under the brand name, Euda Helix茅.
Chemokine was founded by its major shareholder, Professor Kah Meng Lim, a molecular medicine researcher with deep scientific roots. Prof. Lim earned his Ph.D. in Molecular Medicine from the National University of Singapore and spent years in research roles under Singapore鈥檚 national R&D agency, A*STAR. His work bridges academic science and consumer health innovation, and he is widely respected for translating complex biological discoveries into practical health applications.
What Makes Euda Helix茅 Different
Euda Helix茅 is designed to support energy, immune resilience, and cellular health using a formulation that goes beyond traditional supplements. It combines molecular deer placenta, marine collagen and bioactive antioxidants like astaxanthin, L-glutathione, grape seed oil, sea-buckthorn oil and refined avocado oil which it delivers through a capsule system that protects and delivers the ingredients for maximum absorption
Euda Helix茅 is built on a gene activation model designed to modulate gene expression by activating beneficial genes while silencing harmful ones.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward听Looking听Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words 鈥渆stimates,鈥� 鈥減rojected,鈥� 鈥渆xpects,鈥� 鈥渆nvisions,鈥� 鈥渁nticipates,鈥� 鈥渇orecasts,鈥� 鈥減lans,鈥� 鈥渋ntends,鈥� 鈥渂elieves,鈥� 鈥渟eeks,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渇uture,鈥� 鈥減ropose鈥� and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a听number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA鈥檚 control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Chemokine, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail:
FAQ
What is the potential acquisition target for EUDA Health Holdings (NASDAQ: EUDA)?
How long is the exclusivity period in EUDA's LOI with Chemokine?
Who is the founder of Chemokine Pte Ltd?
What is Euda Helix茅 and what makes it unique?
What is the current relationship between EUDA and Chemokine?
